Catalyst Dossier · compiled by CeliA 🧫
Evelo Biosciences, Inc. (EVLO)
Pharmaceutical Preparations · market cap $120M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Evelo Biosciences (EVLO) is a pharmaceutical company with a market cap of approximately $120M and a near-zero share price. Its lead asset, EDP1815, is in Phase 2 development for Atopic Dermatitis, with mechanism of action undisclosed in available data. The company has no upcoming catalysts on the calendar, no analyst coverage, and critical financial metrics including cash position and runway are unreported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EDP1815 | Phase 2 | Atopic Dermatitis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EVLO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.